Axovant Sciences (NYSE: AXON) is down 17% in pre-open trade ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Trader Talk

Eli Lilly (LLY) PT Cut to $92 at Leerink PartnersNovember 23, 2016 2:57 PM BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's FailureNovember 23, 2016 1:48 PM Baird Sees Minimal Read Through for Axovant (AXON) on Lilly's Sola FailureNovember 23, 2016 12:26 PM Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - PiperNovember 23, 2016 11:22 AM Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary EndpointNovember 23, 2016 6:45 AM